Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 02 Jun 2025 for Vir Biotechnology, Inc..
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Jeffrey S. Hatfield: trading record in brief
This profile gathers the share dealings of Jeffrey S. Hatfield across 2 companies, led by Vitae Pharmaceuticals, Inc and Vir Biotechnology, Inc. In total, 17 filings cover trades dated from 22 January 2015 to 30 May 2025.
No open-market purchase appears, only 2 sales worth €1.3M. The rest of the record consists of 7 share grants and 7 option exercises.
On 2 June 2025 came the latest disclosure, a share grant in Vir Biotechnology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Jeffrey S. Hatfield
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
8,000 shares0Common StockSEC:0001628280-25-028892:0
8,000 shares0Common StockSEC:0001628280-24-026193:0
6,027 shares0Common StockSEC:0001209191-23-031841:0
6,405 shares0Common StockSEC:0001209191-22-031949:0
3,374 shares0Common StockSEC:0001209191-21-035706:0
26,537 sharesCommon StockSEC:0001104659-16-091215:0
6 of 6 declarations
